No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
HRTG240816C7500
- 0.71
- +0.06+9.23%
15min DelayClose Jul 22 16:00 ET
0.72High0.15Low
0.15Open0.65Pre Close221 Volume291 Open Interest7.50Strike Price11.35KTurnover91.52%IV7.74%PremiumAug 16, 2024Expiry Date0.12Intrinsic Value100Multiplier25DDays to Expiry0.59Extrinsic Value100Contract SizeAmericanOptions Type0.5798Delta0.2128Gamma9.53Leverage Ratio-0.0148Theta0.0025Rho5.52Eff Leverage0.0078Vega
Intraday
- 5D
- Daily
News
Heritage Announces Second Quarter 2024 Earnings Dates
Heritage Insurance Holdings, Inc. (NYSE: HRTG) ("Heritage" or the "Company"), a super-regional property and casualty insurance holding company, will...
Heritage Insurance Rejoins Russell 3000 Index
Heritage Insurance Holdings Inc. (NYSE: HRTG) ("Heritage" or the "Company"), a super-regional property and casualty insurance holding company, today...
Top 3 Financial Stocks You'll Regret Missing In Q3
The most oversold stocks in the financial sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock's strength on days when prices go up
Investing in Heritage Insurance Holdings (NYSE:HRTG) a Year Ago Would Have Delivered You a 77% Gain
Heritage Insurance(HRTG.US) Director Buys US$38,700 in Common Stock
$Heritage Insurance(HRTG.US)$ Director WHITING PAUL L purchased 5,000 shares of common stock on May 28, 2024 at an average price of $7.74 for a total value of $38,700.Source: Announcement What is stat
Russell 3000 Reshuffle: MITT, ROOT Among Added, EHTH, BKKT Among Deleted
Comments
$Heritage Insurance(HRTG.US$ .. Why so deep down ?
$Heritage Insurance(HRTG.US$ 🐂Heritage Insurance's Board Authorizes New $10 Million Share Repurchase Program . Going up ?
Despite impressive revenue growth, the low P/S ratio may reflect investor concerns of underperformance in the broader industry. The company's medium-term revenue trajectory mirrors the industry's one-year expansion forecast of 6.9%, yet its P/S ratio lags behind industry peers, suggesting some shareholders are bearish and accepting lower selling prices.
1
$C3.ai(AI.US$ $Ambrx Biopharma(AMAM.US$ $BullFrog AI(BFRG.US$ $Biorestorative Therapies(BRTX.US$ $Cardio Diagnostics(CDIO.US$ $Gaotu Techedu(GOTU.US$ $Rubius Therapeutics(RUBY.US$ $Exela Technologies(XELA.US$ $Heritage Insurance(HRTG.US$ $Meten Holding(METX.US$ $Marqeta(MQ.US$ $ObsEva SA(OBSV.US$ $Arcadia Biosciences(RKDA.US$ $Veru Inc(VERU.US$
11
2
Read more